首页 | 本学科首页   官方微博 | 高级检索  
     


New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure
Affiliation:1. Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz – Central Veterans'' Hospital, Lodz, Poland;2. Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland;1. Shandong Key Laboratory of Biophysics, Institute of Biophysics, Dezhou University, Shandong, Dezhou, China;2. Dezhou 2nd People''s Hospital, Shandong, Dezhou, China;1. Division of Internal Medicine, Department of Medicine, Padua University Hospital, Padua, Italy;2. Department of Cardiac, Thoracic and Vascular Sciences, Padua University Hospital, Padua, Italy;3. Anaesthesia and Intensive Care Unit, Department of Medicine, Padua University Hospital, Padua, Italy;4. Infectious Diseases Unit, Padua University Hospital, Padua, Italy;5. General Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, Padua University Hospital, Padua, Italy;1. Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland;2. Department of Nephrology and Internal Medicine, University Hospital, Opole, Poland;1. Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran;2. Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran;3. Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran;4. Department of Immunology, Faculty of Medicine, Zabol University of Medical Sciences, Zabol, Iran;5. Department of Anatomy, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran;6. Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran;1. Division of Oncological Propedeutics, Faculty of Health Sciences, Medical University of Gdansk, Gdynia, Poland;2. Department of Surgical Oncology, Gdynia Oncology Centre, Maritime Polish Red Cross Memorial Hospital, Gdynia, Poland;3. Department of Clinical Nutrition, Medical University of Gdansk, Gdansk, Poland;4. Department of Histology, Medical University of Gdansk, Gdansk, Poland;5. Faculty of Finance and Management, WSB University in Gdansk, Gdansk, Poland;1. Department of Microbiology and Medical Laboratory Immunology, Medical University of Lodz, Lodz, Poland;2. Department of Rheumatology, Medical University of Lodz, Lodz, Poland
Abstract:BackgroundPatients with acute decompensated heart failure (ADHF) are at severe risk of death and rehospitalization. Several clinical studies have been designed to evaluate the efficacy and safety of new molecules administered before discharge or shortly after ADHF. The aim of this article is to summarize current knowledge on recently published findings on treatment of patients with heart failure with reduced ejection fraction (HFrEF) and ADHF.MethodsWe performed a thorough search for literature pertaining to our review via the PubMed database.ResultsIn this review, we summarize original papers concerning the efficacy and safety of new molecules in patients with HFrEF and ADHF.ConclusionsPeri-discharge initiation of treatment with new molecules is possible and safe for patients with HFrEF and ADHF. New molecules, if administered before discharge or shortly after, reduce the risk of cardiovascular death or worsening heart failure within the vulnerable phase, and are also nephroprotective.
Keywords:Acute decompensated heart failure  Vulnerable phase  Heart failure with reduced ejection fraction  Angiotensin receptor/neprilysin inhibitor  Sodium-glucose cotransporter inhibitors
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号